Selection process for the Malaria Box.

<p>Selection process for the Malaria Box.</p

Correlation (Log scale) between the <i>P. falciparum</i> 3D7 and K1 EC₅₀s for the Malaria Box compounds resulting from the confirmatory screen.

<p>Displayed with Vortex (v2012.11.17233) Dotmatics Limited 2007, 2012.</p

Molecular weight distribution for the drug-like set (blue) and probe-like set (green).

<p>Displayed with Vortex (v2012.11.17233) Dotmatics Limited 2007, 2012.</p

Topological Polar Surface Area versus the ALogP for the Malaria Box drug-like set (green) and probe-like set (red).

<p>Displayed with Vortex (v2012.11.17233) Dotmatics Limited 2007, 2012.</p

Principal Component Analysis plots.

<p>Chemical diversity of the GSK, Novartis and St Jude libraries displayed (Panel A); Overlap in chemical diversity of the combined datasets and the commercially available compounds (Panel B); Overlap in chemical diversity of the commercially available compounds where the drug-like and probe-like chemotypes were annotated (Panel C).</p

St Jude's, Novartis and GSK datasets profiled with respect to molecular weight, the number of hydrogen-bond donors, ALogP and N+O (nitrogen count plus oxygen count).

<p>St Jude's, Novartis and GSK datasets profiled with respect to molecular weight, the number of hydrogen-bond donors, ALogP and N+O (nitrogen count plus oxygen count).</p

Venn diagram presenting the overlap of structures in the St. Jude, Novartis and GSK datasets.

<p>The data was generated using Pipeline Pilot 8.5, and displayed using R 2.14.1.</p

Key needs to accelerate <i>Cryptosporidium</i> drug development.

<p>Key needs to accelerate <i>Cryptosporidium</i> drug development.</p

Global drug pipeline.

<p>Global drug pipeline.</p

Projected time periods for introduction of novel malaria technology.

<p>Accelerating toward eradication through innovative tools that monitor (surveillance), prevent (vector control, vaccines), and treat (drugs, diagnostics) malaria.</p